7 February 2024 - NICE has published final evidence-based recommendations on the use of belumosudil mesylate (Rezurock) for the treatment of patients with chronic graft versus host disease.

Belumosudil mesylate is recommended for the treatment of patients 12 years and over with chronic graft versus host disease after two or more systemic treatments only if Sanofi provides it according to the commercial arrangement.

Read NICE technology appraisal guidance